NCT03403036View on ClinicalTrials.gov

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

August 18, 2018

Study Completion Date

August 18, 2018

Conditions
Psoriasis
Interventions
DRUG

Brodalumab

Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

70030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03403036 - Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies | Biotech Hunter | Biotech Hunter